Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brilinta/Bydureon’s Measurable Outcomes Are Smooth Fit For Contracts

Executive Summary

Three-year contracts between AstraZeneca and Harvard Pilgrim focus on reduced hospitalization for Brilinta, reaching HbA1c goals for Bydureon; choosing appropriate products and outcomes are key challenge for the new reimbursement approaches.

You may also be interested in...



The Value Lab: Moving Value-Based Health Care From Theory To Practice

Although stakeholders are interested in value-based models that link a drug’s performance to emerging evidence of improved patient outcomes, such agreements are difficult to implement and too limited in scope to drive a shift to value-based reimbursement. The authors suggest a new, structured approach to bring these contracts into the mainstream, thus transforming product reimbursement and fueling the shift from volume to value.

Disappointing Bydureon EXSCEL Outcomes Data May Raise Stakes For Victoza

AstraZeneca's EXSCEL study could have created confidence in a GLP-1 class-wide outcomes benefit, but instead it has raised questions about whether differences in trial results boil down to trial design.

AstraZeneca Says $3.5bn Brilinta Sales Forecast By 2023 Now Unattainable

AstraZeneca will cut its sales forecasts for Brilinta after the therapy failed to beat the older blood thinner clopidogrel in the comparison EUCLID study in peripheral artery disease.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel